Radius Health Inc (NASDAQ:RDUS) has been assigned a consensus recommendation of “Hold” from the ten brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $34.50.

Several analysts have recently weighed in on RDUS shares. Royal Bank of Canada set a $27.00 price objective on Radius Health and gave the company a “hold” rating in a report on Friday, November 1st. BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a report on Friday, January 3rd. HC Wainwright restated a “hold” rating on shares of Radius Health in a report on Friday, December 20th. Leerink Swann cut their price objective on Radius Health from $49.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, ValuEngine upgraded Radius Health from a “sell” rating to a “hold” rating in a report on Friday, January 24th.

Shares of Radius Health stock traded up $0.21 during trading on Friday, hitting $19.97. The stock had a trading volume of 281,268 shares, compared to its average volume of 543,712. The firm has a market cap of $914.21 million, a P/E ratio of -6.13 and a beta of 0.89. The business has a fifty day moving average of $19.43 and a two-hundred day moving average of $23.45. Radius Health has a fifty-two week low of $17.36 and a fifty-two week high of $29.97.

Institutional investors have recently made changes to their positions in the company. Great West Life Assurance Co. Can acquired a new stake in shares of Radius Health during the fourth quarter worth $50,000. Sowell Financial Services LLC acquired a new position in Radius Health during the fourth quarter valued at $56,000. Ladenburg Thalmann Financial Services Inc. raised its position in Radius Health by 3,130.7% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,423 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 2,348 shares during the period. Russell Investments Group Ltd. acquired a new position in Radius Health during the fourth quarter valued at $101,000. Finally, NumerixS Investment Technologies Inc raised its position in Radius Health by 33.3% during the fourth quarter. NumerixS Investment Technologies Inc now owns 6,000 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 1,500 shares during the period.

About Radius Health

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Recommended Story: Mutual Funds

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.